STAT+: After decade-long dispute over CRISPR-Cas9, Editas strikes deal with Vertex to cash in
For a decade, leading academic institutes and their associated companies fought a bruising fight over who held patent rights to CRISPR-Cas9. Editas Medicine will now cash in.
For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.
Editas Medicine, the winner of that battle in the U.S., will now cash in.
Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.
What's Your Reaction?
